title: Non-myeloablative conditioning for hemopoietic stem cell transplantation--does it work?
abstract: Allogeneic bone marrow or peripheral blood stem cell transplantation traditionally uses myeloablative regimen for conditioning to enable grafting of donor's stem cells. Animal experiments have shown that a milder non-myeloablative conditioning regimen does allow engraftment to occur. Nonmyeloablative conditioning regimens are low-intensity immunosuppressive treatment given to the recipient before infusion of donor's stem cells. It was reported to have decreased immediate procedural mortality, in particular those secondary to acute graft versus host reaction. However, it did give rise to higher risks of graft rejection, tumour tolerance and disease progression. Fortunately, appropriately administered donor lymphocyte infusion has been shown to establish full donor chimerism (complete donor stem cell grafting in the recipient's bone marrow) and potentiate antitumour effect (graft versus tumour reaction). The reduction of immediate transplant mortality allows the procedure to be carried out in older age groups, patients with concomitant diseases that otherwise would have made the patients unfit for the procedure, patients with non-malignant disorders such as congenital immune deficiencies, autoimmune disorders or thalassaemia majors. The regimen also allows transplantation of genetically manipulated haemopoietic stem cells (gene thrapy) to be carried out more readily in the immediate future. Lastly, the regimen may serve as a platform for immunotherapy using specific T cell clones for anti-tumour therapy with or without the knowledge of known tumour antigen.
authors.affiliation: MAKNA-HUKM Cancer Institute, Hospital UKM, Jalan Yaacob Latif, Cheras, 56000 Kuala Lumpur, Malaysia. cheong@mail.hukm.ukm.my
authors.forename: S-K
authors.initials: SK
authors.lastname: Cheong
authors.forename: G-I
authors.initials: GI
authors.lastname: Eow
authors.forename: C-F
authors.initials: CF
authors.lastname: Leong
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007167:Immunotherapy; D019653:Myeloablative Agonists / Q000494:pharmacology*; D019172:Transplantation Conditioning / Q000379:methods*
chemical_list: D019653:Myeloablative Agonists